Study of mutagenic effects with predicted carcinogenicity of 4-((5-decylthio)-4-methyl-4-H-1,2,4-triazole-3-yl)methyl)morpholine for further research in order to create a new drug with antifungal activity




1,2,4-triazole derivatives, mutagens, carcinogens, antitumor activity, cytogenetic activity


The development of effective and safe therapeutic agents using 1,2,4-triazole derivatives is gaining momentum in today’s conditions. The value of such drugs is determined by the rapid and prolonged biological action, which is not accompanied by abrupt changes in homeostasis and pronounced side effects, which are characteristic of most pharmacological drugs of synthetic origin. In the context of a limited range of domestic antimicrobial and antifungal veterinary drugs on the national pharmaceutical market, one of the directions for solving this problem is the search, study, research, and development of drugs with antimicrobial and antifungal activity.

The aim of this work was to study the mutagenic effects with the prediction of carcinogenicity of 4-((5-decylthio)-4-methyl-4-H-1,2,4-triazole-3-yl)methyl)morpholine with the prospect of further creation of new dosage forms for the treatment fungal pathologies of the skin.

Materials and methods. Staph was used to study the effect of 4-((5-decylthio)-4-methyl-4-H-1,2,4-triazol-3-yl)methyl)morpholine in vitro Staphylococcus aureus, strain 209, its UV-2, UV-3 mutants and primary cell cultures. Accounting for gene mutations of microorganisms in the system of metabolic activation (Ames test) was carried out according to the method of L. M. Fonshtein in accordance with the requirements of “Methodological recommendations for assessing the mutagenic properties of new medicinal products” (Kyiv, 1996), supplemented by the methodology according to the recommendations of “Preclinical research of veterinary medicinal products” (edited by I. Ya. Kotsiumbas).

Results. The results of studying the activity of 4-((5-decylthio)-4-methyl-4-H-1,2,4-triazole-3-yl)methyl)morpholine on a model of culture of tumor ascetic cells showed that at concentrations of 1.4 mg/ml, 0.8 mg/ml, 0.3 mg/ml, 0.015 mg/ml it was led to the regression of tumor cells of Ehrlich’s carcinoma and C-37 sarcoma. In experiments with the Nk/L y strain, the same concentrations of 4-((5-decylthio)-4-methyl-4-H-1,2,4-triazole-3-yl)methyl)morpholine significantly slowed down cell growth. The results of the studies indicate a pronounced cytogenetic effect of thiophosfamide and sarcolysin, which suggests their metabolic activation in the body, as evidenced by a pronounced aberration of chromosomes. When comparing the cytogenetic effect of equimolar concentrations, the absence of cytogenetic activity of 4-((5-decylthio)-4-methyl-4-H-1,2,4-triazole-3-yl)methyl)morpholine was revealed.

Conclusions. The positive results of studying the specific activity of 4-((5-decylthio)-4-methyl-4-Н-1,2,4-triazole-3-yl)methyl)morpholine in experiments in vitro were obtained which indicates the expediency of its extensive study in experimental animal tumors. In addition, according to these studies, no mutagenic effect was found at the doses that were used to predict carcinogenicity. Thus, it can be concluded that there is no cytogenetic effect.

Author Biographies

I. V. Bushuieva, Zaporizhzhia State Medical University, Ukraine

PhD, DSc, Professor, Head of the Department of Management and Pharmacy Economics, Medical and Pharmaceutical Law

K. V. Petrova, Bogomolets National Medical University, Kyiv, Ukraine

PhD student

B. P. Kyrychko, Poltava State Agrarian University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Surgery and Midwifery

V. V. Parchenko, Zaporizhzhia State Medical University, Ukraine

PhD, DSc, Professor of the Department of Natural Sciences for Foreign Students and Toxicological Chemistry


Martynyshyn V. P., Hunchak, V. M., Panasenko, O. I., Parchenko, V. V., & Shcherbyna R. O. (2019). Sposib likuvannia dermatolohichnykh zakhvoriuvan [Method of treatment of dermatological diseases]. Ukraine Patent UA 138684.

Shcherbyna, R., Parchenco, V., Martynyshyn, V., & Hunchak, V. (2018). Evaluation of acute and subacute toxicity of oil liniment based on 4-((5-(decylthio)-4-methyl-4H-1,2,4-triazol-3-yl)methyl)morpholine. Ankara Universitesi Eczacilik Fakultesi Dergisi, 42(1), 43-52.

Sokmen, B. B., Gumrukcuoglu, N., Ugras, S., Sahin, H., Sagkal, Y., & Ugras, H. I. (2015). Synthesis, antibacterial, antiurease, and antioxidant activities of some new 1,2,4-triazole schiff base and amine derivatives. Applied biochemistry and biotechnology, 175(2), 705-714.

Kotsiumbas, I. Ya., Malyk, O. H., Patereha, I. P., Tishyn, O. L., & Kosenko, Yu. M. (2006). Doklinichni doslidzhennya veterynarnykh likarskykh zasobiv [Preclinical studies of veterinary medicinal products]. Triada plius. [in Ukrainian].

Stefanov, O. V. (Ed.). (2001). Doklinichni doslidzhennya likarskih zasobiv [Preclinical studies of medicines]. Kyiv: Avitsena. [in Ukrainian].

Ministry of Education and Science. (2012, November 19). Polozhennia pro Komitet z pytan etyky (bioetyky) [Regulations on the Committee on Ethics (Bioethics) (No. 1287)].

Bushueva, I. V., Parkhomenko, L. I., Knysh, Ye. H., & Panasenko, O. I. (2014). Zastosuvannia morfolinii 2-[5-(pirydyn-4-il)-1,2,4-triazol-3-iltio]atsetatu dlia likuvannia i profilaktyky deiakykh zakhvoriuvan [Application of the morpholines of 2-[5-(pyridin-4-yl)-1,2,4-triazol-3-ylthio] acetates for the treatment and prevention of some diseases]. Zaporozhye medical journal, (2), 97-99. [in Ukrainian].

Borisenko, N. N., Bushuieva, I. V., Parchenko, V. V., Gubenko, I. Ya., Mykhailiuk, Ye. О., Riznyk, O. I., Aleksieiev, O. G., Gutyj, B. V., Lysianska, H. P., & Kurinnyi, A. V. (2019). Anti-Inflammatory, Antiviral Veterinary Medicine with Immuno-Modulating Activity. Research Journal of Pharmacy and Technology, 12(11), 5255-5259.

Klosova, X. G., Bushueva, I. V., Parchenko, V. V., Shcherbyna, R. O., Samura, T. O., Gubenko, I. Y., Gutyj, B. V., & Khariv, I. I. (2019). Trifuzol suppositories usage results on the course of endometrial inflammatory processes in cows. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 10(1), 1215-1223.

Bushueva, I., Parchenko, V., Shcherbyna, R., Safonov, A., Kaplaushenko, A., Gutyj, B., & Hariv, I. (2017). Tryfuzol – new original veterinary drug. Ankara Universitesi Eczacilik Fakultesi Dergisi, 41(1), 42-49.

Bushuieva, I. V., Berezovskyi, A. V., Knysh, Ye. H., & Panasenko, O. I. (2014). Zastosuvannia preparatu "Avesstym" dlia pidvyshchennia efektyvnosti vaktsynoprofilaktyky ta vplyv preparatu na rezystentnist kurchat [Use of the drug "Avastin" to increase the effectiveness of vaccination and the effect of the drug resistance of chickens]. Science Rise, 4(1), 94-97. [in Ukrainian].

Borisenko, N. N., Gubenko, I. Y., Parchenko, V. V., & Bushueva, I. V. (2019). The efficacy tests results of the veterinary drug "Trifuzol 1% solution for injection". Research Journal of Pharmaceutical, Biological and Chemical Sciences, 10(1), 102-107.

Bushueva, I. V., Kirichko, B. P., Knish, E. G., Panasenko, О. I., & Izdepskiy V. I. (2014). Vyvchennia vplyvu morfolinii 2-[5-(pirydyn-4-il)-1,2,4-triazol-3-iltio]atsetatu na profilaktyku stresovykh staniv [The study of morpholinium 2-[5-(pyridin-4yl)-1,2,4-triazol-3-ylthio]acetate effect on prevention of stressful conditions]. Current issues in pharmacy and medicine: science and practice, (2), 64-66. [in Ukrainian].



How to Cite

Bushuieva IV, Petrova KV, Kyrychko BP, Parchenko VV. Study of mutagenic effects with predicted carcinogenicity of 4-((5-decylthio)-4-methyl-4-H-1,2,4-triazole-3-yl)methyl)morpholine for further research in order to create a new drug with antifungal activity. Current issues in pharmacy and medicine: science and practice [Internet]. 2022Nov.15 [cited 2024Jul.21];15(3):271-6. Available from:



Original research